Stock Analysis

Daiken Medical Second Quarter 2025 Earnings: EPS: JP¥11.10 (vs JP¥10.20 in 2Q 2024)

TSE:7775
Source: Shutterstock

Daiken Medical (TSE:7775) Second Quarter 2025 Results

Key Financial Results

  • Revenue: JP¥2.52b (up 2.3% from 2Q 2024).
  • Net income: JP¥319.0m (up 8.9% from 2Q 2024).
  • Profit margin: 13% (in line with 2Q 2024).
  • EPS: JP¥11.10 (up from JP¥10.20 in 2Q 2024).
earnings-and-revenue-growth
TSE:7775 Earnings and Revenue Growth November 4th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Daiken Medical Earnings Insights

Looking ahead, revenue is forecast to grow 7.9% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Japan.

Performance of the Japanese Medical Equipment industry.

The company's shares are up 1.4% from a week ago.

Risk Analysis

What about risks? Every company has them, and we've spotted 2 warning signs for Daiken Medical you should know about.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.